BRAF	chr7	140,730,664	140,924,929	-	NA	NA	NA	NA	Expanded	Yes	Yes	No	Duplication/CN gain	GOF	AML	3A	NA	Optical Genome Mapping detected a [Duplication/CN gain] mutation involving the BRAF gene on chr7 with a variant allele frequency (VAF) of [%].	In the context of AML, the activating V600E BRAF mutation is found in 50% of Langerhans cell histiocytosis (LCH) myeloid neoplasms (PMID: 34996063) and is consdered a molecular marker of hairy cell leukemia (HCL) present in >95% of cases (WHO, PMID: 35732829). BRAF mutations are found in <1% of MDS cases "with clinical implications that are likely similar to those of NRAS mutations" (Lindsley (2013) PMID:22934674)
RUNX1T1	chr8	91,954,967	92,103,286	-	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 = 10%; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	No	Yes	Yes	No	Duplication/CN gain	GOF	AML	1A	NA	Optical Genome Mapping detected a translocation t(8;21)(q22;q22.1) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(8;21)(q22;q22.1) is a recurrent abnormality resulting in a RUNX1::RUNX1T1 fusion. In the context of AML it is considered to have a favourable favorable prognosis mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization. Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)
TYK2	chr19	10,350,532	10,380,572	-	NA	NA	NPM1	NA	No	Yes	No	Yes	Duplication/CN gain	GOF	AML	1A if fused with NPM1, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(5;19)(q35;p13) with a variant allele frequency (VAF) of [%]	In the context of AML, this is a rare, recurrent abnormality resulting in a NPM1::TYK2 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (ICC, PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
PDGFRB	chr5	150,113,839	150,155,872	-	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with PDGFRB rearrangement, (ICC, PMID: 35767897).	t(5;12)(q32;p13.2)/ ETV6::PDGFRB	>30 partners (ETV6, PDE4DIP, TPM3, SPTBN1, GOLGA4, WDR48, GOLGB1, PRKG2, CD74, TNIP1, HECW1, HIP1, KANK1, CCDC6, CAPRIN1, ERC1, BIN2, SART3, GIT2, NIN, CCDC88C, TRIP11, TP53BP1, NDE1, RABEP1, MPRIP, SPECC1, MYO18A, COL1A1, DTD1, ZMYND8)	No	Yes	Yes	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	Excellent response to TKI	Optical Genome Mapping detected a _______ translocation resulting in a ______::PDGFRB fusion gene with a variant allele frequency of [].	In the context of AML, The ____::PDGFRB fusion is a recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and will likely respond well to tyrosine kinase inhibitors (PMID: 35767897).
JAK2	chr9	4,984,390	5,129,948	+	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, (WHO, PMID: 35732831).	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; myeloid/lymphoid neoplasm with JAK2 rearrangement, (ICC, PMID: 35767897).	t(8;9)(p22;p24.1)/ PCM1::JAK2	ETV6, BCR, PCM1	Core	Yes	Yes	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	Limited responses to ruxolitinib	Optical Genome Mapping detected a translocation t(9;12)(p24;p13), t(9;22)(p24;q11.2), or t(8;9)(p22;p24.1) with the JAK2 gene (9p24.1) with a variant allele frequency of ___.	In the context of AML, The ETV6::JAK2, BCR::JAK2, or PCM1::JAK2 fusion is a rare, but recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and may respond to targeted therapy (limited response to ruxolitib). The BCR fusion is oncogenic, PCM1 is likely oncogenic and ETV6 is unknown.
BCL11B	chr14	99,169,287	99,272,197	-	Classification of T-ALL, (WHO, PMID: 35732831).	Early T-cell precursor ALLwith BCL11B rearrangement, (ICC, PMID: 35767897).	NA	NA	No	Yes	No	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	NA	Optical Genome Mapping detected a [Duplication/CN gain/rearrangement/translocation] mutation involving the BCL11B gene on chr14 with a variant allele frequency (VAF) of [%].	NA
KMT2A	chr11	118,436,456	118,526,832	+	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with KMT2A rearrangement, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A = 10%. Classification of AML with percentage of blasts required for diagnosis; AML with other KMT2A rearrangements† = 10%, (ICC, PMID: 35767897).	AFF1, AFDN, MLLT3, MLLT10, TET1, ELL, MLLT1	NA	Core	Yes	Yes	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	NA	Optical Genome Mapping detected a [Duplication/CN gain/rearrangement/translocation] mutation involving the KMT2A gene on chr11 with a variant allele frequency (VAF) of [%].	In the context of AML, t(v;11q23.3)/KMT2A-rearrangement associated with _____ risk category in the context of AML based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Over 100 KMT2A fusion partners have been described where the seven most frequent translocation partners account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once (PMID: 37019990). AFF1, AFDN, MLLT10, TET1, ELL and MLLT1 fusion partners are associated with adverse risk categorization whereas MLLT3 is associacted with intermediate risk (ELN, PMID: 35797463). The presence of t(9;11)(p21.3;q23.3) MLLT3::KMT2A takes precedence over rare, concurrent adverse risk gene mutations. t(v;11q23.3)/KMT2A-rearrangement is associated with adverse risk category excluding KMT2A partial tandem duplication (PTD)(ELN, PMID: 35797463).
FGFR1	chr8	38,400,215	38,468,834	-	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with FGFR1 rearrangement, (ICC, PMID: 35767897).	t(8;13)(p11.2;q12.1)/ ZMYM2::FGFR1	15 other partners including BCR (ZMYM2, TPR, RANBP2, LRRFIP1, SQSTM1, CUX1, TRIM24, FGFR1, HOOK3, CNTRL, FGFR1OP2, CPSF6, MYO18A, ERVK3-1, BCR)	Expanded	Yes	Yes	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	High rate of response to FGFR inhibitor such as pemigatinib, especially for cases in chronic phase	Optical Genome Mapping detected a ____ translocation resulting in a ____:::FGFR1 fusion gene at a variant allele frequency of [%].	In the context of AML, the _____ fusion is a recurrent rearrangement seen in 8p11 Myeloproliferative Syndrome and may respond to targeted FGFR inhibitor(s). (PMID: 35767897).
PDGFRA	chr4	54,229,280	54,298,245	+	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusion; Myeloid/lymphoid neoplasm with PDGFRA rearrangement, (ICC, PMID: 35767897).	Cryptic deletion at 4q12/ FIP1L1::PDGFRA	CDK5RAP2; STRN; KIF5B; TNKS2; ETV6, BCR	No	Yes	Yes	No	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	Excellent response to TKI	Optical Genome Mapping detected a translocation or deletion of the PDGFRA gene (4q12) with the CDK5RAP2, STRN, FIP1L1, KIF5B, TNKS2, ETV6, or BCR gene with a variant allele frequency of ___.	In the context of AML, the CDK5RAP2::PDGFRA, STRN::PDGFRA, FIP1L1::PDGFRA, KIF5B::PDGFRA, TNKS2::PDGFRA, ETV6::PDGFRA, or BCR::PDGFRA fusion is a recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and will likely respond well to tyrosine kinase inhibitors. This fusion is likely oncogenic (except for TNKS2::PDGFRA) and has a likely gain of function mutation effect (PMID: 35767897).
FLT3	chr13	28,003,274	28,100,592	-	NA	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions; Myeloid/lymphoid neoplasm with FLT3 rearrangement (ICC, PMID: 35767897)., (ICC, PMID: 35767897).	t(12;13)(p13.2;q12.2)/ ETV6::FLT3	ZMYM2, TRIP11, SPTBN1, GOLGB1, CCDC88C, MYO18A, BCR, ETV6	Core	Yes	Yes	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	Various responses to specific FLT3 inhibitors	Optical Genome Mapping detected a translocation of the ETV6 gene (12p13.2) with the FLT3 gene (13q12.2) with a variant allele frequency of ___.	In the context of AML, the FLT3:: fusion is a rare, but recurrent rearrangement seen in myeloid and lymphoid neoplasia with eosinophilia and may respond to specific FLT3 inhibitors (PMID: 35767897).
RARA	chr17	40,309,180	40,357,643	+	Acute myeloid leukaemia with defining genetic abnormalities; Acute promyelocytic leukaemia with PML::RARA fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2)/PML::RARA = 10%; APL with other RARA rearrangements* = 10%, (ICC, PMID: 35767897).	PML, BCOR, FIP1L1, TBL1XRA, STAT3, STAT5B, ZBTB16, NPM1, IRF2BP2	NA	No	Yes	Yes	No	Duplication/CN gain/rearrangement/translocation	FUS/GOF	APL, AML	1A	NA	Optical Genome Mapping detected a translocation t(15;17)(q24;q21) or t(5;17)(q35.1;q21.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(15;17) is a recurrent abnormality fusing the PML and RARA genes (canonical fusion) or forming a NPM1::RARA fusion. In the context of AML, PML::RARA is considered to have a favorable prognosis and NPM1::RARA prognosis is unclear according to the ELN 2022. the NPM1::RARA, ZBTB16::RARA, STAT5B::RARA, STAT3::RARA, TBL1XR1::RARA, FIP1L1::RARA, BCOR::RARA fusions are rare, atypical, but recurrent variant RARA translocations (PMID: 35797463).
PML	chr15	73,994,673	74,047,827	+	Acute myeloid leukaemia with defining genetic abnormalities; Acute promyelocytic leukaemia with PML::RARA fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2)/PML::RARA = 10%, (ICC, PMID: 35767897).	NA	NA	No	Yes	Yes	Yes	Duplication/CN gain/rearrangement/translocation	FUS/GOF	APL	1A	NA	Optical Genome Mapping detected a translocation t(15;17)(q24;q21) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(15;17) is a recurrent abnormality fusing the PML and RARA genes (canonical fusion). In the context of AML it is considered to have a favorable prognosis according to the ELN 2022. (PMID: 35797463).
NUP98	chr11	3,671,083	3,797,792	-	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with NUP98 rearrangement, (WHO, PMID: 35732831).	NA	NSD1, KMD5A	NA	No	No	No	No	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A	NA	Optical Genome Mapping detected a translocation t(11;12)(p15.4;p13.3), t(5;11)(q35.2;p15.4), or t(11;v)(p15.4;v) with a variant allele frequency (VAF) of [%	In the context of AML, this is a rare, recurrent abnormality resulting in a NUP98::KMD5A or NUP98::NSD1 or NUP98::v fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
GATA2	chr3	128,479,427	128,493,201	-	NA	Classification of AML with percentage of blasts required for diagnosis; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2; MECOM(EVI1) = 10%. Hematologic neoplasms with germline predisposition associated with a constitutional disorder affecting multiple organ systems; Myeloid neoplasms with germline GATA2 mutation. Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition and potential organ dysfunction., (ICC, PMID: 35767897).	NA	NA	Core	Yes	Yes	No	Duplication/CN gain/rearrangement/translocation	FUS/GOF	AML	1A if fused to MECOM, otherwise 3A	NA	Optical Genome Mapping detected a t(3;3)(q21.3;q26.2).	In the context of AML, this is a recurrent abnormality resulting in a GATA2::MECOM(EVI1) fusion associated with adverse risk prognosis in the context of AML (PMID: 35797463).
MYH11	chr16	15,703,135	15,857,028	-	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with CBFB::MYH11 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 = 10%, (ICC, PMID: 35767897).	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A	NA	Optical Genome Mapping detected a translocation inv(16)(p13.1q22) or t(16;16)(p13.1;q22) which is a recurrent abnormality resulting in a CBFB::MYH11 fusion.	In the context of AML it is considered to have a favourable favorable prognosis mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization (ELN, PMID: 35797463)
CBFB	chr16	67,028,984	67,101,058	+	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with CBFB::MYH11 fusion., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 = 10%., (ICC, PMID: 35767897).	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused with MYH11, otherwise 3A	NA	Optical Genome Mapping detected a translocation inv(16)(p13.1q22) or t(16;16)(p13.1;q22) which is a recurrent abnormality resulting in a CBFB::MYH11 fusion.	In the context of AML it is considered to have a favourable favorable prognosis mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization (ELN, PMID: 35797463)
ABL2	chr1	179,099,329	179,229,677	-	NA	NA	NA	NA	Expanded	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the ABL2 gene on chr1 with a variant allele frequency (VAF) of [%].	NA
ALK	chr2	29,192,773	29,921,586	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the ALK gene on chr2 with a variant allele frequency (VAF) of [%].	NA
BIN2	chr12	51,281,037	51,324,174	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the BIN2 gene on chr12 with a variant allele frequency (VAF) of [%].	NA
CDK5RAP2	chr9	120,388,874	120,580,167	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the CDK5RAP2 gene on chr9 with a variant allele frequency (VAF) of [%].	NA
CDX2	chr13	27,960,917	27,969,315	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the CDX2 gene on chr13 with a variant allele frequency (VAF) of [%].	NA
CNTRL	chr9	121,074,954	121,177,610	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the CNTRL gene on chr9 with a variant allele frequency (VAF) of [%].	NA
CRLF2_chrX	chrX	1,190,489	1,212,649	NA	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the CRLF2_chrX gene on chrX with a variant allele frequency (VAF) of [%].	NA
CRLF2_chrY	chrY	1,190,489	1,212,649	NA	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the CRLF2_chrY gene on chrY with a variant allele frequency (VAF) of [%].	NA
EBF1	chr5	158,695,919	159,099,916	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the EBF1 gene on chr5 with a variant allele frequency (VAF) of [%].	NA
EP300	chr22	41,092,591	41,180,077	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the EP300 gene on chr22 with a variant allele frequency (VAF) of [%].	NA
EPOR	chr19	11,377,206	11,384,314	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the EPOR gene on chr19 with a variant allele frequency (VAF) of [%].	NA
EWSR1	chr22	29,268,267	29,300,521	+	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the EWSR1 gene on chr22 with a variant allele frequency (VAF) of [%].	NA
FEV	chr2	218,981,086	218,985,184	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the FEV gene on chr2 with a variant allele frequency (VAF) of [%].	NA
FIP1L1	chr4	53,377,640	53,460,862	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the FIP1L1 gene on chr4 with a variant allele frequency (VAF) of [%].	NA
GATA1	chrX	48,786,589	48,794,311	+	NA	NA	NA	NA	Expanded	Yes	Yes	No	Rearrangement/translocation	FUS	AML	3A	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the GATA1 gene on chrX with a variant allele frequency (VAF) of [%].	NA
GIT2	chr12	109,929,803	109,996,368	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the GIT2 gene on chr12 with a variant allele frequency (VAF) of [%].	NA
GOLGA4	chr3	37,243,270	37,366,879	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the GOLGA4 gene on chr3 with a variant allele frequency (VAF) of [%].	NA
HIP1	chr7	75,533,297	75,738,941	-	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the HIP1 gene on chr7 with a variant allele frequency (VAF) of [%].	NA
KANK1	chr9	504,694	746,103	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the KANK1 gene on chr9 with a variant allele frequency (VAF) of [%].	NA
KIF5B	chr10	32,009,014	32,056,425	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the KIF5B gene on chr10 with a variant allele frequency (VAF) of [%].	NA
MRTFA	chr22	40,410,281	40,636,719	-	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RBM15::MRTFA fusion, (WHO, PMID: 35732831).	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	1A	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the MRTFA gene on chr22 with a variant allele frequency (VAF) of [%].	NA
MYB	chr6	135,181,307	135,219,172	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the MYB gene on chr6 with a variant allele frequency (VAF) of [%].	NA
NIN	chr14	50,719,762	50,831,162	-	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the NIN gene on chr14 with a variant allele frequency (VAF) of [%].	NA
NTRK3	chr15	87,859,750	88,256,739	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the NTRK3 gene on chr15 with a variant allele frequency (VAF) of [%].	NA
P2RY8_chrX	chrX	1,462,580	1,537,185	NA	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the P2RY8_chrX gene on chrX with a variant allele frequency (VAF) of [%].	NA
P2RY8_chrY	chrY	1,462,580	1,537,185	NA	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the P2RY8_chrY gene on chrY with a variant allele frequency (VAF) of [%].	NA
PCM1	chr8	17,922,987	18,029,948	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the PCM1 gene on chr8 with a variant allele frequency (VAF) of [%].	NA
PDE4DIP	chr1	148,844,427	149,033,016	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the PDE4DIP gene on chr1 with a variant allele frequency (VAF) of [%].	NA
PRKG2	chr4	81,087,374	81,215,222	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the PRKG2 gene on chr4 with a variant allele frequency (VAF) of [%].	NA
RABEP1	chr17	5,282,283	5,386,340	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the RABEP1 gene on chr17 with a variant allele frequency (VAF) of [%].	NA
SPTBN1	chr2	54,456,326	54,671,446	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the SPTBN1 gene on chr2 with a variant allele frequency (VAF) of [%].	NA
STIL	chr1	47,250,138	47,314,147	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the STIL gene on chr1 with a variant allele frequency (VAF) of [%].	NA
STRN	chr2	36,837,697	36,966,536	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the STRN gene on chr2 with a variant allele frequency (VAF) of [%].	NA
TAL1	chr1	47,216,290	47,232,225	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the TAL1 gene on chr1 with a variant allele frequency (VAF) of [%].	NA
TP53BP1	chr15	43,403,060	43,493,156	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the TP53BP1 gene on chr15 with a variant allele frequency (VAF) of [%].	NA
USP2	chr11	119,355,214	119,381,690	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the USP2 gene on chr11 with a variant allele frequency (VAF) of [%].	NA
WDR48	chr3	39,052,015	39,096,664	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the WDR48 gene on chr3 with a variant allele frequency (VAF) of [%].	NA
ZMYM2	chr13	19,958,726	20,089,115	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the ZMYM2 gene on chr13 with a variant allele frequency (VAF) of [%].	NA
ZNF292	chr6	87,155,564	87,265,943	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	2	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the ZNF292 gene on chr6 with a variant allele frequency (VAF) of [%].	NA
MLLT3	chr9	20,341,669	20,622,499	-	NA	Classification of AML with percentage of blasts required for diagnosis; AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A = 10%, (ICC, PMID: 35767897).	KMT2A	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused to KMT2A, otherwise 3A	NA	Optical Genome Mapping detected a [Rearrangement/translocation] mutation involving the MLLT3 gene on chr9 with a variant allele frequency (VAF) of [%].	In the context of AML, t(9;11)(p21.3;q23.3)/MLLT3::KMT2A is associated with interemediate risk category in the context of AML based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverserisk gene mutations. (ELN, PMID: 35797463)
GLIS2	chr16	4,316,066	4,339,595	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	1A if fused to CBFA2T3, otherwise 3A	NA	Optical Genome Mapping detected a translocation inv(16)(p13.3q24.3) with a variant allele frequency (VAF) of [%	In the context of AML, the inv(16)(p13.3q24.3) is a rare, recurrent abnormality resulting in a CBFA2T3::GLIS2 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
RBM15	chr1	110,338,506	110,346,681	+	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RBM15::MRTFA fusion, (WHO, PMID: 35732831).	NA	MRTF1	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A	NA	Optical Genome Mapping detected a translocation t(1;22)(p13.3;q13.1) with a variant allele frequency (VAF) of [%	In the context of AML, the t(1;22)(p13.3;q13.1) is a rare, recurrent abnormality resulting in a RBM15::MRTF1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
PRDM16	chr1	3,069,202	3,438,621	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused with RPN1, otherwise, 3A	NA	Optical Genome Mapping detected a translocation t(1;3)(p36.3;q21.3) with a variant allele frequency (VAF) of [%	In the context of AML, the t(1;3)(p36.3;q21.3) is a rare, recurrent abnormality resulting in a PRDM16::RPN1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
RPN1	chr3	128,619,968	128,650,818	-	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused with PRDM16, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(1;3)(p36.3;q21.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(1;3)(p36.3;q21.3) is a rare, recurrent abnormality resulting in a PRDM16::RPN1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
PICALM	chr11	85,957,174	86,069,084	-	NA	NA	MLLT10	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused with MLLT10, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(10;11)(p12.3;q14.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(10;11)(p12.3;q14.2) is a rare, recurrent abnormality resulting in a PICALM::MLLT10 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
MLLT10	chr10	21,534,231	21,743,630	+	NA	NA	KMT2A, PICALM	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused to KMT2A or PICALM, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(10;11)(p12.3;q23.3) or t(10;11)(p12.3;q14.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(10;11)(p12.3;q23.3) is a recurrent abnormality resulting in a MLLT10::KMT2A fusion. the t(10;11)(p12.3;q14.2) is a rare, recurrent abnormality resulting in a PICALM::MLLT10 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). In the context of AML, MLLT10::KMT2A fusion is considered to have a adverse favorable prognosis according to the ELN 2022, the PICALM::MLLT10 fusion has an unclear prognosis due to its rarity (PMID: 35797463).
TET1	chr10	68,560,336	68,694,487	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused with KMT2A, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(10;11)(q21.3;q23.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(10;11)(q21.3;q23.3) is a recurrent abnormality resulting in a TET1::KMT2A fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).
ELL	chr19	18,442,662	18,522,070	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	1A if fused to KMT2A, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(11;19)(q23.3;p13.1) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(11;19)(q23.3;p13.1) is a recurrent abnormality resulting in a ELL::KMT2A fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).
MLLT1	chr19	6,210,380	6,279,975	-	NA	NA	KMT2A	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused to KMT2A, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(11;19)(q23.3;p13.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(11;19)(q23.3;p13.3) is a recurrent abnormality resulting in a MLLT1::KMT2A fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).
ERG	chr21	38,380,035	38,498,477	-	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	1A if fused to FUS, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(16;21)(p11.2;q22.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(16;21)(p11.2;q22.2) is a rare, recurrent abnormality resulting in a FUS::ERG fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
FUS	chr16	31,180,138	31,191,605	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	1A if fused to ERG, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(16;21)(p11.2;q22.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(16;21)(p11.2;q22.2) is a rare, recurrent abnormality resulting in a FUS::ERG fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
AFF1	chr4	86,935,010	87,141,039	+	NA	NA	NA	NA	No	Yes	No	Yes	Rearrangement/translocation	FUS	AML	1A if fused to KMT2A, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(4;11)(q21.3;q23.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(4;11)(q21.3;q23.3) is a recurrent abnormality resulting in a AFF1::KMT2A fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).
NSD1	chr5	177,133,772	177,300,213	+	NA	NA	NUP98	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused to NUP98, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(5;11)(q35.2;p15.4) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(5;11)(q35.2;p15.4) is a rare, recurrent abnormality resulting in a NUP98::NSD1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
AFDN	chr6	167,826,910	167,972,023	+	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	1A if fused to KMT2A, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(6;11)(q27;q23.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(6;11)(q27;q23.3) is a recurrent abnormality resulting in a AFDN::KMT2A fusion. In the context of AML it is considered to have a adverse prognosis according to the ELN 2022 (PMID: 35797463).
DEK	chr6	18,223,860	18,264,548	-	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with DEK::NUP214 fusion., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 = 10%., (ICC, PMID: 35767897).	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused to NUP214, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(6;9)(p22.3;q34.1) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(6;9)(p22.3;q34.1) is a recurrent abnormality resulting in a DEK::NUP214 fusion. In the context of AML it is considered to have a adverse favorable prognosis according to the ELN 2022 (PMID: 35797463).
NUP214	chr9	131,125,573	131,234,663	+	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with DEK::NUP214 fusion, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 = 10%, (ICC, PMID: 35767897).	NA	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A	NA	Optical Genome Mapping detected a translocation t(6;9)(p22.3;q34.1) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(6;9)(p22.3;q34.1) is a recurrent abnormality resulting in a DEK::NUP214 fusion. In the context of AML it is considered to have a adverse prognosis according to the ELN 2022 (PMID: 35797463).
CREBBP	chr16	3,725,053	3,880,713	-	NA	NA	NA	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused to KAT6A, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(8;16)(p11.2;p13.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(8;16)(p11.2;p13.3) is a rare, recurrent abnormality resulting in a KAT6A::CREBBP fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). KAT6A::CREBBP associated with adverse risk category (ELN, PMID: 35797463).
KAT6A	chr8	41,929,478	42,051,987	-	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused to CREBBP, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(8;16)(p11.2;p13.3) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(8;16)(p11.2;p13.3) is a rare, recurrent abnormality resulting in a KAT6A::CREBBP fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). KAT6A::CREBBP associated with adverse risk category (ELN, PMID: 35797463).
ABL1	chr9	130,713,043	130,887,675	+	Acute myeloid leukaemia with BCR::ABL1 fusion, (WHO, PMID: 35732831).	AML with t(9;22)(q34.1;q11.2)/BCR::ABL1§ = 20%, (ICC, PMID: 35767897).	BCR	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused with BCR, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(9;22)(q34.1;q11.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(9;22)(q34.1;q11.2) is a recurrent abnormality resulting in a BCR::ABL1 fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).
BCR	chr22	23,179,704	23,318,037	+	Acute myeloid leukaemia with defining genetic abnormalities; acute myeloid leukaemia with BCR::ABL1 fusion. , (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with t(9;22)(q34.1;q11.2)/BCR::ABL1§ = 20%. Classification of B-ALL; B-ALLwith t(9;22)(q34.1;q11.2)/BCR::ABL1, B-ALL, BCR::ABL1–like, ABL-1 class rearranged, B-ALL, BCR::ABL1–like, JAK-STAT activated, B-ALL, BCR::ABL1–like, NOS, (ICC, PMID: 35767897).	ABL1	NA	No	Yes	Yes	Yes	Rearrangement/translocation	FUS	AML	1A if fused with ABL1, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(9;22)(q34.1;q11.2) with a variant allele frequency (VAF) of [%]	In the context of AML, the t(9;22)(q34.1;q11.2) is a recurrent abnormality resulting in a BCR::ABL1 fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).
MLF1	chr3	158,571,193	158,606,456	+	NA	NA	NA	NA	No	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A if fused to NPM1, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(3;5)(q25.3;q35.1) with a variant allele frequency (VAF) of [%]	In the context of AML, this is a rare, recurrent abnormality resulting in a NPM1::MLF1 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (ICC, PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
CBFA2T3	chr16	88,874,857	88,977,207	-	NA	NA	NA	NA	No	Yes	No	No	Rearrangement/translocation	FUS	AML	1A if fused to RUNX1 or GLIS2, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(16;21)(q24.3;q22.1) or inv(16)(p13.3q24.3) with a variant allele frequency (VAF) of [%]	In the context of AML, this is a rare, recurrent abnormality resulting in a RUNX1::CBFA2T3 or CBFA2T3::GLIS2 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity (PMID: 35767897). Due to the rarity of this translocation the prognosis is unclear.
MECOM	chr3	169,083,499	169,663,775	-	Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with MECOM rearrangement, (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2; MECOM(EVI1) = 10%. Classification of AML with percentage of blasts required for diagnosis; AML with other MECOM rearrangements‡ = 10%, (ICC, PMID: 35767897).	GATA2, MYC, ETV6, RUNX1	NA	Expanded	Yes	Yes	No	Rearrangement/translocation	FUS	AML	1A	NA	Optical Genome Mapping detected a t(3;8)(q26.2;q24.2), t(3;12)(q26.2;p13.2), t(3;21)(q26.2;q22.1), inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2).	In the context of AML, this is a recurrent abnormality resulting in a GATA2::MECOM(EVI1), MYC::MECOM, ETV6::MECOM, RUNX1::MECOM or novel t(3q26.2;v)/MECOM(EVI1)-rearrangement associated with adverse risk category (ELN, PMID: 35797463)
